Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.

doi:10.1016/J.BMCL.2005.04.056

Paper

Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.

Published Jun 15, 2005 · V. Garaj, L. Puccetti, G. Fasolis

Bioorganic & medicinal chemistry letters

Q2 SJR score

151

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Highly Cited

Study Snapshot

Novel sulfonamides incorporating 1,3,5-triazine moieties effectively inhibit carbonic anhydrase I, II, and IX, offering potential for novel hypoxic tumor management approaches.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.

Sign up to use Study Snapshot

References

Carbonic Anhydrase: Its Inhibitors and Activators

Carbonic anhydrase inhibitors and activators have potential therapeutic applications in ophthalmology, cancer, and various other fields.

Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH

Hypoxia activates tumor-associated carbonic anhydrase IX to acidify extracellular pH, potentially impacting tumor progression and treatment outcomes.

Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.

Sulfonamides incorporating triazinyl moieties show potential as novel anticancer strategies targeting hypoxic areas of tumors, particularly clear renal cell carcinoma.

Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion

CAIX plays a crucial role in tumor cell growth and survival under normoxia and hypoxia, but is not involved in invasion, making it a potential target for cancer therapy.

Modulation of carbonic anhydrase activity and its applications in therapy

Modulation of carbonic anhydrase activity through inhibitors or activators leads to various therapeutic applications, including glaucoma treatment, antiepileptics, and cognitive disorders.

Citations

Discovery of Promising Sulfadiazine Derivatives With Anti‐Proliferative Activity Against Tumor Cell Lines

Promising pyrimidine sulfonamide derivatives show anti-proliferative activity against multiple cancer cell lines, making them potential candidates for future anticancer drug development.

Benzimidazole‐Containing Compounds as Anticancer Agents

Benzimidazole-containing compounds show potential as a promising scaffold for developing novel anti-cancer agents targeting biological targets like VEGFR, PI3 K, EGFR kinase, PARPs, and HAT/HDAC.

Homoleptic Co(II) and Ni(II) complexes with promising anticancer and antimicrobial activities; Synthesis, X-ray structure, and DFT studies

Homoleptic Co(II) and Ni(II) complexes show promising antibacterial and antifungal activities, surpassing gentamycin and ketoconazole, and show potential as anticancer therapeutic agents.

Synthesis, X-ray Structure, Cytotoxic, and Anti-Microbial Activities of Zn(II) Complexes with a Hydrazono s-Triazine Bearing Pyridyl Arm

Zn(II) complexes with a hydrazono s-triazine bearing pyridyl arm show promising cytotoxic and antimicrobial activities against cancer cells, with potential as anticancer agents.

Innovation of 6-sulfonamide-2H-chromene derivatives as antidiabetic agents targeting α-amylase, α-glycosidase, and PPAR-γ inhibitors with in silico molecular docking simulation

6-sulfonamide-2H-chromene derivatives show potential anti-diabetic activity by targeting -amylase, -glucosidase, and PPAR-, with acceptable oral bioavailability and safe toxicity profiles.